A special issue dedicated to the 2021 meeting of the French Society for Nanomedicine.
Résumé
The field of nanomedicine has reached a milestone since the approval of Patisiran, the first ever-approved siRNA drug designed to treat transthyretin (TTR) amyloidosis. The great success of Corminaty and Spikevax messenger RNA (mRNA)-based vaccines against COVID-19 has really brought to light how potent nanomedicine could be. Today, stakeholders are getting more confident in the benefits of nanomedicine for diagnosis, treatment, vaccination, and research related to different types of diseases. For the years to come, it is becoming clear that we need a multidisciplinary approach to achieve a rational design of nanomedicine. Impelling the meeting and discussions of academic and private actors from different disciplines is one of the goals of the French Society for Nanomedicine (SFNano).
Fichier principal
Editorial note for the special issue SFNano 2021 of the International Journal of Pharmaceutics_FinalVersion.pdf (21.54 Ko)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|